Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 4/2018

01-10-2018 | Letter to the Editor

Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers

Authors: Fay Kastrinos, Hajime Uno, Sapna Syngal

Published in: Familial Cancer | Issue 4/2018

Login to get access

Excerpt

We appreciate the opportunity to comment on the recently published article by Goverde et al. entitled, “Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers” [1]. …
Literature
1.
2.
Kastrinos F, Uno H, Ukaegbu C et al (2017) Development and validation of the PREMM5 model for comprehensive risk assessment of lynch syndrome. J Clin Oncol 35(19):2165–2172CrossRef
Metadata
Title
Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers
Authors
Fay Kastrinos
Hajime Uno
Sapna Syngal
Publication date
01-10-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-018-0074-6

Other articles of this Issue 4/2018

Familial Cancer 4/2018 Go to the issue

Original Article

Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk

Original Article

The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome

Original Article

Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same

Original Article

A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC)

Original Article

Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation

Original Article

SNP association study in PMS2-associated Lynch syndrome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits